I. RFA-HG-12-009 Clinical Sequencing Exploratory Research (U01)
II. NOT-DA-12-013 National Institute on Drug Abuse (NIDA) Seeks Applications Using the JAX Diversity Outcross (DO) Mice
III. Multidisciplinary Studies of HIV/AIDS and Aging )(R21, R01, R03)
PAR-12-174 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-174.html) R21
PAR-12-175 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-175.html) R01
PAR-12-176 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-176.html) R03
IV. Model Organisms to Human Biology – Cancer Genetics Conference
I. RFA-HG-12-009 Clinical Sequencing Exploratory Research (U01)
The NHGRI and NIDA seek grant applications to explore, within an active clinical setting, the application of genomic sequence data to the care of patients. Our understanding of human genetic variation and its association with disease risk and with individual response to treatment continues to expand rapidly. Simultaneously, a revolution has occurred in genomic sequencing technologies, making it technically and economically feasible to consider the application and utilization of genomic sequence data in clinical care. Applications submitted in response to this FOA will address critical questions about the application of genomic sequencing to clinical care of individual patients, from generation of genomic sequence data, to interpretation and translation of the data for the physician, to communication to the patient, including an examination of the ethical, legal and psychosocial implications of bringing broad genomic data into the clinic.
Letter of Intent due June 26th, 2012
Applications are due: July 26, 2012, by 5:00 PM local time of applicant organization.
If interested, please contact:
Joni L. Rutter, PhD
Acting Director
Division of Basic Neuroscience and Behavioral Research
National Institute on Drug Abuse/NIH/DHHS
301.435.0298
II. NOT-DA-12-013 National Institute on Drug Abuse (NIDA) Seeks Applications Using the JAX Diversity Outcross (DO) Mice
The Genetics and Molecular Neurobiology Research Branch (GMNRB) at the National Institute on Drug Abuse (NIDA) seeks applications using the JAX Diversity Outcross (DO) mice to identify genetic variants associated with substance abuse and addiction as well as treatment response. To apply for grants within this area of interest, refer to PA-11-026 Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01) (http://grants.nih.gov/grants/guide/pa-files/PA-11-026.html).
The diversity outcross mice permit fine mapping of genetic loci for complex trait with far less effort and greater resolution than before with other mouse resources. Papers highlighting this resource can be found in the Feb 16, 2012 issues of Genetics www.genetics.org and G3: Genes|Genomes|Genetics www.g3journal.org.
Identification the gene variants underlying the following traits DO mice that are of interest to GMNRB include but are not limited to:
· Motivation to work for a drug as measured by drug self-administration breakpoint.
· Persistence of drug seeking behavior
· Compulsivity of drug seeking behavior
· Preference between drug and sucrose following drug self-administration and the absence of any withdrawal symptoms
· Withdrawal
· Tolerance
· Sensitization
· Novelty seeking
· Different measures of impulsivity, e.g. 5CSRTT (five-choice serial reaction time task) and reversal learning
· Goal trackers vs. sign Trackers, i.e. difference in cue reactivity and auto-shaping.
· Measures of anxiety associated with drug seeking behavior.
· Altered brain circuitry following drug exposure
· Drug Toxicity
· Pharmacokinetics
· Phenotypes produced by GXE interactions that may affect substance abuse and addiction phenoytpes such as maternal separation, victimization by aggression, learned helplessness in utero exposure to drugs of abuse and environmental toxins such as lead, and vulnerability to drugs of abuse during puberty and early adulthood.
· Genetic modifiers of knockout mouse phenotypes affecting drug response.
· Treatment response to pharmacological agents that have potential for treating substance abuse
· Nicotine, cocaine, and heroin vaccine responses such antibody titer and amount of free and bound drug in tissues.
The JAX:DO are available from The Jackson Laboratory (Bar Harbor, ME), as JAXMice stock number 009376. Sibling information at each generation is tracked and made available upon request. http://cgd.jax.org/datasets/phenotype/SvensonDO.shtml.
Inquiries
Please direct all inquiries to:
Jonathan D. Pollock, Ph.D.
Chief
Genetics and Molecular Neurobiology Research Branch
Division of Basic Neuroscience and Behavioral Research
National Institute on Drug Abuse
6001 Executive Blvd. Rm 4103
Bethesda, MD 20892
(For Fedex Delivery the address is Rockville, MD 20852)
Telephone: 301-435-1309
FAX: 301-594-6043
Email. jpollock@mail.nih.gov
III. Multidisciplinary Studies of HIV/AIDS and Aging )(R21, R01, R03)
PAR-12-174 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-174.html) R21
PAR-12-175 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-175.html) R01
PAR-12-176 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-176.html) R03
This FOA invites applications proposing to study HIV infection, HIV-associated conditions, HIV treatment, and/or biobehavioral or social factors associated with HIV/AIDS in the context of aging and/or in older adults. Research approaches of interest include clinical translational, observational, and intervention studies in domestic and international settings.
IV. Model Organisms to Human Biology – Cancer Genetics Conference
The Genetics Society of America invites you to attend the Model Organisms to Human Biology – Cancer Genetics Conference, co-sponsored by NCI and in Washington, D.C., June 17-21, 2012 at the Omni Shoreham Hotel. This interactive meeting will bring together investigators who study cancer-relevant problems in model organisms with those who study human cancer. Keynote speakers include Bert Vogelstein, Eric Lander and Angelika Amon. Eric Green, Director, NHGRI, will chair a mini-symposium on modENCODE at MOHB. This GSA Conference dovetails with the NIH-sponsored symposium on June 20 -21, which marks the completion of the ModENCODE project. Chris Kaiser, Director-Designate, NIGMS, will also make a presentation. For the complete agenda, invited speakers and to register for the MOHB-Cancer Genetics Conference, please see www.mohb.org/2012/. Deadline for early (discounted) registration: May 10, 2012.
----
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov<mailto:listserv@list.nih.gov>, Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email
- You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment